$0.606
-0.129 (-21.26%)At close
- High
- 1.100
- Open
- 0.748
- VWAP
- 0.77
- Vol
- 29.75M
- Mkt Cap
- 207.53M
- Low
- 0.600
- Amount
- 22.87M
- EV/EBITDA, TTM
- 0.01
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Valuation Metrics
Events Timeline
News
9.006-04Yahoo Finance23andMe seeks new bids after $305 million offer from its co-founder
9.004-02TipRanksBlockchain Projects Race to Rescue DNA Data as 23andMe Declares Bankruptcy
6.503-28NASDAQ.COMHow to Tune Out Market Noise
9.003-26Newsfilter23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
9.003-26CNBC23andMe co-founder lashes out at CEO Wojcicki after bankruptcy filing, says board lacked oversight
ME FAQ — answered by Alphio AI
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.